Table 2.

Treatments for MDS in patients with and without the AIMs.

	All patients (n = 61)	MDS with AIMs (n = 12)	MDS without AIMs (n = 49)	P∗
Supportive care
Transfusion, n (%)	20 (32.8)	2 (16.7)	18 (36.7)	.37
Anabolic steroid, n (%)	2 (3.3)	0 (0)	2 (4.1)	1.00
Hematopoietic growth factor
G-CSF, n (%)	2 (3.3)	0 (0)	2 (4.1)	1.00
Epo, n (%)	7 (11.5)	0 (0)	7 (14.3)	.33
TPO-RA, n (%)	2 (3.3)	0 (0)	2 (4.1)	1.00
Immunosuppressive therapy
PSL, n (%)	2 (3.3)	0 (0)	2 (4.1)	1.00
CsA, n (%)	4 (6.6)	1 (8.3)	3 (6.1)	1.00
Hypomethylating agent, n (%)	3 (4.9)	2 (16.7)	1 (2.0)	.10
Hematopoietic stem cell transplantation, n (%)	6 (9.8)	2 (16.7)	4 (8.2)	.33
Others
Clinical trial, n (%)	1 (1.6)	0 (0)	1 (2.0)	1.00
No treatment, n (%)	31 (50.8)	8 (66.7)	23 (46.9)	.34

AIMs = autoimmune manifestations, CsA = cyclosporin A, Epo = erythropoietin, G-CSF = granulocyte-colony stimulating factor, MDS = myelodysplastic syndrome, PSL = prednisolone, TPO-RA = thrombopoietin-receptor agonist.

^∗Calculated by Fisher's exact test.